# US 2013/0251683 A1 · Prolonged delivery of heparin-binding growth factors from heparin-derivatized collagen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251683 A1
- Document ID: US20130251683A1
- Status: Published application
- Kind: A1
- Application number: 13/762,225
- Filed: 2013-02-07
- Published: 2013-09-26
- Earliest claimed: 2007-10-09
- Assignees: Genzyme Corporation
- Applicants: Genzyme Corporation
- Inventors: Michael Santos; Michael Philbrook; Michael A. DiMicco; Robert J. Miller
- Web page: https://patentgrep.com/patent/US20130251683A1

## CPC

- A61K 9/0002: {Galenical forms characterised by the drug release technique; Application systems commanded by energy}
- A61K 35/761: Adenovirus
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/1875: {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24}
- A61L 27/24: Collagen
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C12N 15/86: Viral vectors
- A61L 2300/258: Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
- A61L 2300/414: Growth factors
- A61L 2300/602: Type of release, e.g. controlled, sustained, slow
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a heparin-derivatized collagen matrix comprising a fragment of heparin covalently linked to a collagen scaffold, wherein the fragment of heparin has molecular weight of less than about 15 kDa, and at least one heparin-binding growth factor (HBGF) or heparin-binding adeno-associated virus (HB-AAV) or a combination thereof and methods for promoting bone growth, bone repair, cartilage repair, bone development, neo-angiogensis, wound healing, tissue engraftment and muscle tissue regeneration and/or tissue augmentation comprising administering a heparin-derivatized collagen matrix that includes at least one heparin-binding growth factor or heparin-binding adeno-associated virus or a combination thereof.

## Claims

### Claim 1

A heparin-derivatized collagen matrix comprising a fragment of heparin covalently linked to a collagen scaffold, wherein the fragment of heparin has molecular weight of less than about 15 kDa, and at least one heparin-binding growth factor (HBGF) or heparin-binding adeno-associated virus (HB-AAV) or a combination thereof.

### Claim 2 (depends on 1)

The heparin-derivatized collagen matrix of claim 1, wherein the HBGF is selected from the group consisting of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), heparin-binding epidermal growth factor (HBEGF), the transforming growth factor-β (TGF-β) superfamily, keratinocyte growth factor (KGF), pleiotrophin, placental growth factor (PlGF), hepatocyte growth factor, interferon-gamma (IFN-gamma), platelet-derived growth factor (PDGF), interleukin-8 (IL-8), macrophage inflammatory protein-1 (MIP-1), interferon-gamma-inducible protein-10 (IP-10) or HIV-Tat transactivating factor and combinations thereof.

### Claim 3 (depends on 2)

The heparin-derivatized collagen matrix of claim 2, wherein the HBGF is at least one member of the TGF-β superfamily.

### Claim 4 (depends on 3)

The heparin-derivatized collagen matrix of claim 3, wherein the HBGF is bone morphogenetic protein 2 (BMP-2).

### Claim 5 (depends on 1)

The heparin-derivatized collagen matrix of claim 1, wherein the HB-AAV is selected from the group consisting of AAVs that promote the expression of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), heparin-binding epidermal growth factor (HBEGF), the transforming growth factor-b (TGF-β) superfamily, keratinocyte growth factor (KGF), pleiotrophin, placental growth factor (PlGF), hepatocyte growth factor, interferon-gamma (IFN-gamma), platelet-derived growth factor (PDGF), interleukin-8 (IL-8), macrophage inflammatory protein-1 (MIP- 1), interferon-gamma-inducible protein-10 (IP-10) or HIV-Tat transactivating factor and combinations thereof.

### Claim 6 (depends on 5)

The heparin-derivatized collagen matrix of claim 5, wherein HB-AAV is adeno-associated virus-2 (AAV-2) that promotes the expression of one of the members of the TGF-β superfamily.

### Claim 7 (depends on 6)

The heparin-derivatized collagen matrix of claim 6, wherein the HB-AAV is adeno-associated virus-2 (AAV-2) that promotes the expression of bone morphogenetic protein 2 (BMP-2).

### Claim 8 (depends on 1)

The heparin-derivatized collagen matrix of claim 1, wherein the fragment of heparin has a molecular weight less than about 15 kDa.

### Claim 9 (depends on 8)

The heparin-derivatized collagen matrix of claim 8, wherein the fragment of heparin has a molecular weight between about 12 kDa and 13 kDa.

### Claim 10 (depends on 8)

The heparin-derivatized collagen matrix of claim 8, wherein the fragment of heparin has a molecular weight between about 5 kDa and 6 kDa.

### Claim 11 (depends on 1)

The heparin-derivatized collagen matrix of claim 1, wherein the HBGF or HB-AAV or a combination thereof promotes bone growth, bone repair and/or bone development.

### Claim 12 (depends on 1)

The heparin-derivatized collagen matrix of claim 1, wherein the HBGF or HB-AAV or a combination thereof promotes cartilage repair.

### Claim 13

A method of promoting bone or cartilage growth, repair and/or development comprising administering a heparin-derivatized collagen matrix comprising a fragment of heparin covalently linked to a collagen scaffold, wherein the fragment of heparin has a molecular weight of less than about 15 kDa, and at least one heparin-binding growth factor (HBGF) or heparin-binding adeno-associated virus (HB-AAV) or a combination thereof.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A method of promoting neo-angiogenesis comprising administering the heparin-derivatized collagen matrix of claim 1.

### Claim 16

A method of promoting tissue regeneration or augmentation comprising administering a heparin-derivatized collagen matrix comprising a fragment of heparin covalently linked to a collagen scaffold, wherein the fragment of heparin has a molecular weight of less than about 15 kDa, and at least one heparin-binding growth factor (HBGF) or heparin-binding adeno-associated virus (HB-AAV) or a combination thereof.

### Claim 17

(canceled)
